Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Oct. 10, 2016 -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting at the upcoming 2016 BIO Investor Forum being held October 18-19, 2016 at the Westin St. Francis Hotel in San Francisco, California. Ocera’s presentation will take place in the Elizabethan B Room at 8:30 AM Pacific Time.
A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com. A replay of the presentation will be available for 60 days following the conference for those unable to listen live.
About Ocera
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com.
OCRX-G
Contact: Susan Sharpe Ocera Therapeutics, Inc. [email protected] 919-328-1109
